- FDA investigates cholesterol drug (Moldova.org)
The U.S. Food and Drug Administration said it is investigating a report of a possible increased cancer risk for patients who take the drug Vytorin.Vytorin is a combination of Simvastatin, marketed as Zocor, and ezetimibe, marketed as Zetia. It was approved as a combination drug in 2004 to reduce LDL-choloesterol levels.Preliminary results of a clinical trial to see if lowering LDL-cholesterol ...
- FDA Investigates Possible Vytorin-Cancer Link (US News & World Report)
But the agency says patients can still take the cholesterol-lowering drug
- London News and Reviews (Evening Standard)
A pill that lowers cholesterol and is taken by thousands of Britons has been linked to an increased risk of cancer. Drug safety chiefs in the U.S. are investigating a report of possible higher cancer rates among patients taking Inegy, a pill combining two kinds of medication.
- Cholesterol pill taken by thousands linked to increased risk of cancer (Daily Mail)
A pill that lowers cholesterol and is taken by thousands of Britons has been linked to an increased risk of cancer among patients taking Inegy, a pill combining two kinds of medication.
- FDA Investigates Possible Vytorin-Cancer Link (US News & World Report)
THURSDAY, Aug. 21 (HealthDay News) -- U.S. drug regulators said Thursday that they were investigating whether the cholesterol-lowering drug Vytorin might be linked to cancer.
- FDA to Explore Possible Vytorin-Cancer Link (MedicineNet.com)
Title: FDA to Explore Possible Vytorin-Cancer Link Category: Health News Created: 8/22/2008 Last Editorial Review: 8/22/2008
- FDA investigates cholesterol drug (UPI)
WASHINGTON, Aug. 23 (UPI) -- The U.S. Food and Drug Administration said it is investigating a report of a possible increased cancer risk for patients who take the drug Vytorin.
- Cholesterol-lowering drug may up cancer risk (New Kerala)
London, Aug 23 : A cholesterol-lowering drug can raise the risk of cancer, suggests a new research. Inegy is taken by thousands of people in the UK and the drug regulator is studying research which has linked to indicated a link to increased cancers and deaths from cancer.
- FDA Needs Nine More Months To Study Vytorin, Cancer Link (PharmaceuticalOnline)
Once the FDA receives the final data from the pharmaceutical manufacturers' study, it anticipates a six-month evaluation period, with a conclusion expected about nine months from now.
- ORIGINAL ARTICLE: SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study (New England Journal of Medicine)
A genomewide screen of patients with myopathy who were taking high-dose Simvastatin (80 mg per day) showed a strong association between myopathy and variants of SLCO1B1, which encodes an organic anion-transporting polypeptide. Approximately 60% of the cases of myopathy could be attributed to these variants. The association was replicated in an independent study. Genotyping SLCO1B1 variants may ...